These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26553769)

  • 1. Role of Immune Therapies for Myeloma.
    Rosenblatt J; Avigan D
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1440-7. PubMed ID: 26553769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
    Ray A; Das DS; Song Y; Richardson P; Munshi NC; Chauhan D; Anderson KC
    Leukemia; 2015 Jun; 29(6):1441-4. PubMed ID: 25634684
    [No Abstract]   [Full Text] [Related]  

  • 6. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
    Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
    Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V; Borrello I
    Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and vaccine immunotherapy for multiple myeloma.
    Garfall AL; Stadtmauer EA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):521-527. PubMed ID: 27913524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.
    Suen H; Brown R; Yang S; Ho PJ; Gibson J; Joshua D
    Leukemia; 2015 Jul; 29(7):1621-2. PubMed ID: 25987102
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in immunotherapy in multiple myeloma.
    Boussi L; Niesvizky R
    Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic approaches to treat multiple myeloma.
    Roeven MW; Hobo W; Schaap N; Dolstra H
    Hum Vaccin Immunother; 2014; 10(4):896-910. PubMed ID: 24335570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cell therapy in multiple Myeloma.
    Vallet S; Pecherstorfer M; Podar K
    Expert Opin Biol Ther; 2017 Dec; 17(12):1511-1522. PubMed ID: 28857616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
    Liegel J; Avigan D; Rosenblatt J
    Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
    Cohen AD
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.